Logo

Junshi Entered into a Collaboration with DotBio to Develop Cancer Therapies

Share this

Junshi Entered into a Collaboration with DotBio to Develop Cancer Therapies

Shots:

  • DotBio is eligible to receive up front and milestones along with royalties as the molecule advanced through clinical development, regulatory approvals, and commercialization
  • Junshi Biosciences gets the license to one of DotBio’s DotBody modules for use in oncology to develop multi-specific cancer therapies.
  • DotBio’s technology platform is based on the concept of modular design & helps to produce Abs with high efficiency and quality. The technology has been developed for autonomous folding, better stability, high expression levels, high concentration, and low aggregation

Ref: Globe Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions